Canada markets closed
LATEST UPDATE

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

We are taking a short break, but we will be back next week. Stay tuned!

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.6400-0.0100 (-1.54%)
At close: 3:59PM EDT
Full screen
Previous Close0.6500
Open0.6600
Bid0.6300 x N/A
Ask0.6500 x N/A
Day's Range0.6200 - 0.6600
52 Week Range0.1900 - 1.2400
Volume214,774
Avg. Volume448,400
Market Cap43.35M
Beta (5Y Monthly)N/A
PE Ratio (TTM)16.00
EPS (TTM)0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

    Achieving its second FDA orphan drug designation with ketamine.Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.Seeking to enter Phase 2 clinical trial in 2022. TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug desi

  • GlobeNewswire

    PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

    “KET-LID” trial to evaluate ketamine’s safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s diseaseTORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient sc

  • GlobeNewswire

    PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

    TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor. Dr. Laughren will advise on regulatory matters as it pertains to KETABET™, the Company’s patented combination formulation of FDA-approved ketamine and betaine, as a potential next-generation treatment for neuropsychiat